Ligand Pharmaceuticals Incorporated (LGND) Financials
LGND Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| March 31, 2026 | 1.5 billion | 534.8 million |
| Dec. 31, 2025 | 1.6 billion | 543.4 million |
| Sept. 30, 2025 | 1.5 billion | 526.6 million |
| June 30, 2025 | 948.6 million | 120.1 million |
LGND Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| March 31, 2026 | 48.5 million | 10.6 million |
| Dec. 31, 2025 | 45.8 million | 14.3 million |
| Sept. 30, 2025 | 13.1 million | 14.7 million |
| June 30, 2025 | 15.6 million | 10.0 million |
LGND Net Income
Graph available only for paid members. Upgrade to see it.
| Date | Net Income |
|---|---|
| March 31, 2026 | -13.3 million |
| Dec. 31, 2025 | 44.8 million |
| Sept. 30, 2025 | 117.3 million |
| June 30, 2025 | 4.8 million |
LGND Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| March 31, 2026 | 779.4 million | 446.9 million | 4.0 million |
| Dec. 31, 2025 | 733.5 million | 446.2 million | 4.2 million |
| Sept. 30, 2025 | 664.5 million | 445.5 million | 5.5 million |
| June 30, 2025 | 255.3 million | - | 5.7 million |
LGND Shares Outstanding
LGND Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| March 31, 2026 | 228000 | 2.1 million | 20.8 million | - |
| Dec. 31, 2025 | 9000 | 3.5 million | 25.0 million | - |
| Sept. 30, 2025 | 15000 | 21.0 million | 28.4 million | - |
| June 30, 2025 | 214000 | 6.6 million | 20.2 million | - |
LGND Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| March 31, 2026 | 51.7 million | 2.1 million |
| Dec. 31, 2025 | 59.7 million | -26.0 million |
| Sept. 30, 2025 | 115.5 million | 24.8 million |
| June 30, 2025 | 47.6 million | 2.9 million |
LGND Revenue by Segment
Graph available only for paid members. Upgrade to see it.
LGND
Price: $253.25
52 week price:
Payout Ratio Range:
Earnings Per Share: 7.67 USD
P/E Ratio: 27.09
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 186100
Ebitda: 19.2 millionMarket Capitalization: 4.7 billion